Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICE: Naxitamab with Chemotherapy for Refractory Neuroblastoma
NCT06438614Phase 2Completed
- Sponsor
- Fundació Sant Joan de Déu
- Start
- Aug 2020
- Primary completion
- Jul 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of naxitamab in neuroblastoma, sponsored by Fundació Sant Joan de Déu. Primary endpoints: Number of Participants with Serious and Non-Serious Adverse Events at 14 months, Best Overall Response (at the end of HITS treatment) at 39 days and 7 more. Started Aug 2020; status: completed.
02
Drugs
naxitamab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT06438614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06438614.